Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution

Journal of Acquired Immune Deficiency Syndromes

Volumn 31, Issue 5, 2002, Pages 514-520

  Mynarcik, Dennis C ^a   Combs, Terry ^b   McNurlan, Margaret A ^a   Scherer, Philipp E ^b   Komaroff, Eugene ^a   Gelato, Marie C ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Acrp30 Insulin resistance; HIV lipodystrophy; Leptin Adiponectin

Indexed keywords

ADIPONECTIN; LEPTIN;

ADULT; ARTICLE; BODY FAT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LEAN BODY WEIGHT; LIMB; LIPODYSTROPHY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY;

EID: 0037114893     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200212150-00009     Document Type: Article

References (41)

1. Carr AS, Burton S, Law M, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-8.
2. Liss M, Boyle BA. HAART-associated body habitus and metabolic changes, part 1. AIDS Read 2000;10:622, 629-31.
3. Mynarcik DC, McNurlan MA, Steigbigel RT, et al. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr 2000;25:312-21.
4. Saint-Marc T, Partisani M, Poizot-Martin I, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in pafients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study. AIDS 2000;14:37-49.
5. Vigouroux CG, Salhi S, Nguyen Y, et al. Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease. Diabetes Metab 1999;25:383-92.
6. Hadigan CC, Basgoz N, Davis B, et al. Mefformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. JAMA 2000;284:472-7.
7. Hardy H, Esch LD, Morse GD. Glucose disorders associated with HIV and its drug therapy. Ann Pharmacother 2001;35:343-51.
8. Jain RG, Furfine ES, Pedneault L, et al. Metabolic complications associated with antiretroviral therapy. Antiviral Res 2001;51:151-77.
9. Seip M, Trygstad O. Generalized lipodystrophy, congenital and acquired (lipoatrophy). Acta Paediatr Suppl 1996;413:2-28.
10. Hegele RA. Insulin resistance in human partial lipodystrophy. Curr Atheroscler Rep 2000;2:397-404.
11. Reitman ML, Arioglu E, Gavrilova O, et al. Lipoatrophy revisited. Trends Endocrinol Metab 2000;11:410-6.
12. Calabrese LH. Changing patterns of morbidity and mortality in HIV disease. Cleve Clin J Med 2001;68:105, 109-10, 112.
13. Liss M, Boyle BA. HAART-associated body habitus and metabolic changes, part 2. AIDS Read 2000;10:688-91.
14. Lo JC, Mulligan K, Tai VW, et al. Buffalo hump in men with HIV-1 infection. Lancet 1998;351:867-70.
15. Miller KDJ, Yanovski E, Shankar R, et al. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998;351:871-5.
16. Roth VR, Kravcik S, Angel JB. Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis 1998;27:65-7.
17. Carr AS, Thorisdottir A, Kaufmann GR, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidemia, and diabetes mellitus: A cohort study. Lancet 1999;353:2093-9.
18. Graham N. Metabolic disorders among HIV-infected patients treated with protease inhibitors: A review. J Acquir Immune Defic Syndr 2000;25(suppl 1):S4-11.
19. Hruz PW, Murata H, Mueckler M. Adverse metabolic consequences of HIV protease inhibitor therapy: The search for a central mechanism. Am J Physiol Endocrinol Metab 2001;280:E549-53.
20. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000;23:35-43.
21. Madge S, Kinloch-de-Loes S, Mercey D, et al. Lipodystrophy in patients naive to HIV protease inhibitors. AIDS 1999;13:735-7.
22. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998;395:763-70.
23. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: An adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002;13:84-9.
24. Farooqi ISK, Kamath JM, Jones S, et al. Partial leptin deficiency and human adiposity. Nature 2001;414:34-5.
25. Montague CTF, Whitehead JP, Soos MA, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997;387:903-8.
26. Oral EAS, Ruiz E, Andewelt A, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002;346:570-8.
27. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941-6.
28. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-23.
29. Wise S, Nielsen MF, Cryer PE, et al. Overnight normalization of glucose concentrations improves hepatic but not extrahepatic insulin action in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 1998;83:2461-9.
30. Abumrad NN, Rabin D, Diamond MP, et al. Use of a heated superficial hand vein as an alternative site for the measurement of amino acid concentrations and for the study of glucose and alanine kinetics in man. Metabolism 1981;30:936-40.
31. Combs TPW, Berger J, Doebber T, et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: A potential mechanism of insulin sensitization. Endocrinology 2002;143:998-1007.
32. Berg AH, Combs TP, Du X, et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001;7:947-53.
33. Considine RVS, Heiman ML, Kriauciunas A, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292-5.
34. Havel PJ, Kasim-Karakas S, Mueller W, et al. Relationship of plasma leptin to plasma insulin and adiposity in normal weight and overweight women: Effects of dietary fat content and sustained weight loss. J Clin Endocrinol Metab 1996;81:4406-13.
35. Maffei M, Halaas J, Ravussin E, et al. Leptin levels in human and rodent: Measurement of plasma leptin and RNA in obese and weight-reduced subjects. Nat Med 1995;1:1155-61.
36. Paganelli R, Mezzaroma I, Mazzone AM, et al. Leptin levels in HIV-positive patients treated with HAART. AIDS 1999;13:2479.
37. Estrada V, Serrano-Rios M, Martinez Larrad MT, et al. Leptin and adipose tissue maldistribution in HIV-infected male patients with predominant fat loss treated with antiretroviral therapy. J Acquir Immune Defic Syndr 2002;29:32-40.
38. Haque W, Shimomura A, Iichiro Y, et al. Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab 2002;87:2395-8.
39. Arita YK, Ouchi N, Takahashi M, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79-83.
40. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930-5.
41. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595-9.